The following is a summary of the Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Artivion reported Q1 revenue of $97.4 million, up 16% year-on-year in constant currency.

• The company saw an adjusted EBITDA growth of 60% compared to Q1 of 2023.

• Product line growth was led by tissue processing at 26%, followed by stent grafts at 19% and On-X at 11% growth compared to Q1 of 2023.

• From a regional standpoint, Latin America saw the most increase with 22%, followed by North America at 18%, while Asia saw a decrease of 3% compared to Q1 2023.

• Artivion's reported GAAP net income for Q1 of 2024 was approximately $7.5 million, or $0.18 per diluted share.

• The company managed to leverage SG&A costs effectively, leading to profitable financial results.

Business Progress:

• Artivion is seeing progress in key operational areas with robust growth in tissue processing, stent grafts, and On-X valves.

• The company released positive clinical data from its On-X low INR post-market study and AMDS persevere trial.

• Regulatory approvals have been secured in key international markets, allowing for expansion.

• The company expects future growth to come primarily from the stent graft business, market share gains of On-X, growth from its proprietary SynerGraft pulmonary valve, and expansion in the APAC and Latin America.

More details: Artivion IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.